Benzinga··Vandana SinghVertex's Kidney Drug Povetacicept Wins Pivotal Trial, Shares Jump 6%+
$VERX surges 6.3% after kidney drug povetacicept achieves Phase 3 trial success with 52% proteinuria reduction, positioning FDA approval by year-end.
VRTXIBBBBHFDA approvalclinical development